6869 Share Price Performance
JP¥0
-2041.50 (-100.00%)
Price JP¥0
Fair ValueJP¥1,732.67
Share Pricen/a
Narrative Update • Aug 01
Sysmex Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
6869 Community Narratives
AN
Fair Value
·Fair Value JP¥1.73k 4.9% undervalued intrinsic discount
Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value JP¥1.38k 19.3% overvalued intrinsic discount
Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value JP¥2.75k 40.0% undervalued intrinsic discount
Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Demographics And Global Expansion Will Drive Long Term Diagnostic Demand
Sysmex makes the machines and supplies hospitals use for everyday lab tests, and demand may keep rising as populations age and more care shifts to routine monitoring. The story hinges on whether global expansion and a bigger range of tests can boost higher-profit consumables, while China’s cost controls and rising expenses could hold growth back.Read more
AN
JP¥2.75k
40.0% undervalued intrinsic discount
Fair Value
Revenue
8.83% p.a.
Profit Margin
13.4%
Future PE
21.23x
Price in 2029
JP¥3.21k
Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings
Sysmex may enjoy steady long-term demand as more people need routine blood and lab testing, but tougher pricing rules and cost controls in China could make growth harder than it looks. See what the company’s push into new regions, more direct selling, and internal efficiency efforts could mean—and what might trip them up.Read more
AN
JP¥1.38k
19.3% overvalued intrinsic discount
Fair Value
Revenue
4.14% p.a.
Profit Margin
8.25%
Future PE
21.38x
Price in 2029
JP¥1.62k
Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects
Sysmex is trying to shift from selling machines to building a steadier, higher‑profit stream from the testing supplies labs use every day, helped by new approvals, partnerships, and a wider sales push outside China. The upside is a broader global footprint and better margins, but policy pressure in China and the risk that costly expansion plans don’t pay off could still derail the story.Read more
AN
JP¥1.73k
4.9% undervalued intrinsic discount
Fair Value
Revenue
6.13% p.a.
Profit Margin
9.54%
Future PE
21.91x
Price in 2029
JP¥2.03k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
6869: Share Buybacks And New Collaboration Will Support Stronger Returns
Fair Value: JP¥2.75k 40.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Diagnostics Demand Will Offset China Headwinds And Support Steady Long-Term Earnings
Fair Value: JP¥1.38k 19.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hemostasis Expansion And Value Chain Reforms Will Reshape Long Term Prospects
Fair Value: JP¥1.73k 4.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sysmex Corporation Key Details
About 6869
- Founded
- 1968
- Employees
- 10861
- CEO
- WebsiteView website
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte counts; coagulation, blood gas/ electrolyte/ urinalysis, cells/ microorganisms, including particle counter/analyzer CDA-1000/1000B, an equipment which is capable of counting cells, yeast, algae, bacteria, and others. The company serves national and other public hospitals, general hospitals, universities, research institutes, other medical institutions, etc. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
